Accordingly, glial fibrillary acid protein (GFAP) and the soluble triggering receptor expressed on myeloid cells 2 (sTREM-2), two established biomarkers of astroglial and microglial activation, have been proposed as prognostic tools in MS [9,10,11,12]. This evidence concerns the gene GFAP and myeloid sarcoma.